SCHEDULE 13G: Vickers Venture Fund and Principals Disclose Significant Stakes in Aardvark Therapeutics

Vickers Venture Fund VI Pte. Ltd., along with its principals Dr. Finian Tan and Christopher Michael Ho, have disclosed beneficial ownership of significant portions of Aardvark Therapeutics, Inc.'s common stock, with Vickers Pte holding 9.58%.

Summary

• Dr. Finian Tan, a Singapore citizen, beneficially owns an aggregate of 1,861,258 shares of Aardvark Therapeutics, Inc. common stock, representing 8.69% of the outstanding shares. This includes 20,000 shares held directly, 13,000 shares held by his wife, 247,818 shares by Vickers Venture Global Deep-tech Fund I L.P., 225,354 shares by Vickers Venture Fund VI (Plan) Pte. Ltd., 1,221,722 shares by Vickers Venture Fund VI Pte. Ltd., and 133,364 shares by Vickers Venture Co-investment LLC.
• Christopher Michael Ho, a United States citizen, beneficially owns an aggregate of 1,694,894 shares, representing 7.92% of the outstanding common stock. These shares are held through Vickers Venture Global Deep-tech Fund I L.P. (247,818 shares), Vickers Venture Fund VI (Plan) Pte. Ltd. (225,354 shares), and Vickers Venture Fund VI Pte. Ltd. (1,221,722 shares).
• Vickers Venture Fund VI Pte. Ltd., a Singapore company, directly beneficially owns 2,050,902 shares, which constitutes 9.58% of Aardvark Therapeutics' common stock.
• The beneficial ownership percentages are calculated based on an aggregate of 21,402,932 shares of Aardvark Therapeutics, Inc. common stock outstanding.
• The filing, a Schedule 13G, indicates that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: This is a factual disclosure of beneficial ownership, providing no direct positive or negative sentiment regarding the company's performance or future prospects. It simply reports significant investor stakes.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

This filing indicates significant institutional investment in Aardvark Therapeutics, Inc., a company likely in the biotechnology or pharmaceutical sector. Such disclosures are common for publicly traded companies as investors cross certain ownership thresholds, providing transparency on major shareholders and their passive investment intent.

Related Party Transactions

• Dr. Finian Tan and Christopher Michael Ho, as directors, manage various Vickers Venture entities (Vickers Venture Global Deep-tech Fund I L.P., Vickers Venture Fund VI (Plan) Pte. Ltd., Vickers Venture Fund VI Pte. Ltd., and Vickers Venture Co-investment LLC) that hold shares in Aardvark Therapeutics, Inc. This establishes an interconnected ownership structure among the reporting persons and the investment vehicles.
• Dr. Tan and Mr. Ho disclaim beneficial ownership of the securities held by these entities, except to the extent of their respective proportionate pecuniary interest therein.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional and individual ownership stakes, which can influence market perception and potential future corporate actions.
• Management: Awareness of large shareholders can influence strategic decisions and engagement.

Key Dates

Keywords

Aardvark Therapeutics, SEC filing, Schedule 13G, Beneficial Ownership, Vickers Venture Fund, Common Stock, Institutional Investor, Biotechnology